2019
Patterns of palliative symptom management (PSM) medication use at end-of-life (EoL) among Medicare beneficiaries with advanced lung cancer (advLC).
Davidoff A, Prsic E, Saphire M, Canavan M, Wang S, McCorkle R, Presley C. Patterns of palliative symptom management (PSM) medication use at end-of-life (EoL) among Medicare beneficiaries with advanced lung cancer (advLC). Journal Of Clinical Oncology 2019, 37: 130-130. DOI: 10.1200/jco.2019.37.27_suppl.130.Peer-Reviewed Original ResearchMedication useEoL-1Medication receiptPoor patient-provider communicationAdvanced lung cancerHigh symptom burdenPatient demographic characteristicsPatient-provider communicationAge 77 yearsMedicare/MedicaidRace/ethnicity groupsNon-Hispanic whitesNausea/ vomitingSymptom burdenHospice enrollmentSymptom reliefConcurrent radiationSEER-MedicareOutpatient settingParenteral medicationsLung cancerMedicare beneficiariesPatientsLogistic regressionOlder adults
2010
Tumor molecular correlates of unresectable, locally advanced head and neck squamous cell carcinoma (SCCHN) response to concurrent radiation (RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG 3303).
Egloff A, Lee J, Vaezi A, Langer C, Forastiere A, Quon H, Burtness B, Grandis J. Tumor molecular correlates of unresectable, locally advanced head and neck squamous cell carcinoma (SCCHN) response to concurrent radiation (RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG 3303). Journal Of Clinical Oncology 2010, 28: 5537-5537. DOI: 10.1200/jco.2010.28.15_suppl.5537.Peer-Reviewed Original Research
2007
Doxorubicin and concurrent radiotherapy for anaplastic thyroid cancer: We need to do better
Lim S, Lee N, Fury M, Ghossein R, Shaha A, Wolden S, Pfister D. Doxorubicin and concurrent radiotherapy for anaplastic thyroid cancer: We need to do better. Journal Of Clinical Oncology 2007, 25: 16506-16506. DOI: 10.1200/jco.2007.25.18_suppl.16506.Peer-Reviewed Original ResearchAnaplastic thyroid cancerProgression-free survivalOverall survivalThyroid cancerRadiation therapyDocumentation of failureConcurrent radiation therapyLocal control rateKaplan-Meier methodPoor prognostic diseaseRT portalsAdvanced diseaseConcurrent radiotherapyPrior surgerySurgical resectionPathology reviewPrognostic diseaseATC casesHistologic subtypeConcurrent radiationPathologic confirmationPathology databaseAggressive malignancyTreatment optionsControl rate
2005
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer
Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. International Journal Of Radiation Oncology • Biology • Physics 2005, 64: 496-504. PMID: 16243442, DOI: 10.1016/j.ijrobp.2005.07.975.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Administration ScheduleFeasibility StudiesFemaleHumansPaclitaxelProspective StudiesRadiation PneumonitisRadiation-Sensitizing AgentsRadiotherapy DosageRadiotherapy, AdjuvantConceptsRadiation therapyBreast cancerAdjuvant doxorubicinConcurrent paclitaxelWeekly paclitaxelAC chemotherapyConcurrent radiationConcurrent treatmentGrade 2 radiation pneumonitisStage IIEarly-stage breast cancerAdjuvant AC chemotherapyDefinitive breast surgeryOperable stage IIWeekly paclitaxel treatmentConcurrent radiation therapyDose-limiting toxicityProtocol-based treatmentAdjuvant chemotherapyPaclitaxel scheduleSteroid therapyCyclophosphamide chemotherapyRadiation pneumonitisPulmonary injuryRadiation dermatitis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply